



SUPPLEMENTARY FIGURES



Supplementary Figure S1: UCHL1 expression is not regulated by MMSET activity in myeloma. **A.** Genome browser tracks (<http://dldcc-web.brc.bcm.edu/lilab/NSD2/>) reflecting histone H3K36me2 ChIP-seq data centered on the transcription start site of the UCHL1 gene. Comparisons are made between replicates if parental KMS-11 cells and those in which the MMSET allele has been deleted (TKO). **B.** Gene expression data (GSE29148) from parental and 2-independent KMS-11 TKO cell lines are shown comparing the expression of *UCHL1*, *BACE2*, and *IRF1*. **C.** Gene expression data (GSE24746) comparing KMS-11 cells, transduced with a doxycycline inducible UCHL1 shRNA, either in the presence or absence of doxycycline. **D.** Gene expression data (also from GSE24746) in which KMS-11 TKO cells are complemented with either empty DS-red expression vector, or those encoding wild-type (WT) MMSET, constitutively active (F1177A) or catalytically inactive (Y1118A) MMSET constructs.



Supplementary Figure S2: Overall disease-related survival of patients with myeloma subdivided by T+C classification, and *UCHL1* level. A–C. Patients treated with TT2 (GSE2658) were classified into T+C groups as described in “Methods”, and the overall survival was estimated using the Kaplan-Meier method with patients stratified based on *UCHL1* level as shown. In all panels, *p* values were calculated with the Mantel-Cox log rank test.